Introduction {#s1}
============

Viral infections overcoming the host sentinel hurdles of cell-intrinsic and innate immune responses are met with well-concerted adaptive immune responses. Adaptive immune responses comprise cellular and humoral effectors, and the central players for each are CD8^+^ cytotoxic T lymphocytes (CTLs) targeting infected cells and neutralizing antibodies (NAbs) targeting viral envelopes (Envs). Normally, a combinational response of these two effectors, initiated and assisted by professional antigen-presenting cells (APCs) such as dendritic cells (DCs) and CD4^+^ helper T lymphocytes (Th), effectively kill and neutralize infected cells and cell-free virus, respectively, resulting in elimination of virus from the infected host.

Unfitting such an optimal course, CCR5^+^ (R5) memory CD4^+^ T cell-tropic (R5-tropic) human immunodeficiency virus (HIV) and pathogenic simian immunodeficiency virus (SIV) infections are met with inefficient adaptive immune responses, resulting in persistent viral replication (Figure [1A](#F1){ref-type="fig"}). CTL responses play a still incomplete yet central role in primary resolution of viremia (Goulder and Watkins, [@B16]), whereas there is a more major impairment in early NAb responses in typical HIV/SIV infections (Tomaras et al., [@B62]). Delayed HIV/SIV-specific NAb induction also accompanies very distinct traits, contrasting other viral infections; firstly, germinal center formation itself is delayed for more than 1 month (Levesque et al., [@B33]; Peruchon et al., [@B50]). Approximately past 3 months post-infection NAbs appear, which is severely delayed, and they repetitively succumb to viral escape (Richman et al., [@B52]). Along this course of NAb development, cross-reactivity against other HIV strains is gradually acquired by NAbs at about year 1 post-infection (Mikell et al., [@B41]). Later on, certain rare patients further proceed to eliciting NAbs showing very extensive cross-reactivity, which became defined as broadly neutralizing antibodies (bNAbs) (Burton et al., [@B9]). These bNAbs can now be identified and characterized by single-cell B-cell receptor cloning (Scheid et al., [@B56]).

![**Viremia patterns in HIV/SIV/SHIV-infected animals receiving interventions including passive NAbs. (A)** Course of persistent viremia in naïve infection. **(B)** Sterile protection against HIV/SIV/SHIV challenge by pre-challenge NAbs. Depending on the type of antibody, anti-HIV bNAbs can provide such protection at modest serum titers. Superacute-phase (1--10d) NAbs similarly mediate elimination of viral reservoirs. Complete elimination of virus (dotted lines) may be evaluated by experimental interventions such as CD8^+^-cell depletion. **(C)** Viremia reduction by subacute-phase post-challenge NAbs. An antibody dose-dependent attainment of viral load reduction (generally 10--1000-fold) is observed. Pharmacological decline of NAb titers and subsequent epitope-specific viral NAb escape results in rebound of viremia. **(D)** Early passive NAb-mediated sustained SIV viremia control by augmented virus-specific T-cell responses. NAb administration near peak viremia provides viral accumulation in DCs and functional augmentation in CTLs(/Th). Depending on combination of host/virus, B-cell responses are alternatively augmented. Neutralizing activity is critical for this modulation. **(E)** Antiretroviral therapy-based transient suppression of SIV viremia for comparison with NAb-based viremia suppression. Early *in vivo* viral dissemination (proportionate to *t*~1~) inversely correlates with the time to post-therapy cessation viremia rebound (*t*~2~). Judged from the uniform outcome of viral rebound, antiretroviral therapy likely does not modulate endogenous host immune responses.](fmicb-07-01739-g0001){#F1}

NAb absence in early infection conversely suggests the importance of identifying anti-HIV antibody defense mechanisms as well as induction strategies. A practical approach for mechanistically analyzing NAb-based HIV control is antibody passive immunization. Here, recent progress on antibody passive immunization experiments in several types of animal AIDS models will be discussed (Table [1](#T1){ref-type="table"}).

###### 

**Anti-HIV/SIV antibody passive immunization in CCR5-tropic immunodeficiency virus-infected animals[^**a**^](#TN1){ref-type="table-fn"}**.

  **Notion**                                                **Ab administration**   **Ab name/property[^b^](#TN2){ref-type="table-fn"}**   **Dosing**             **Host**                 **Challenge Route/Virus[^c^](#TN3){ref-type="table-fn"}**   **Outcome**                                                                                        **References**
  --------------------------------------------------------- ----------------------- ------------------------------------------------------ ---------------------- ------------------------ ----------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------
  Blockade of initial virus replication                     Pre-challenge           b12                                                    25 mg/kg               RM (Rhesus Macaque)      IVa SHIV~SF162P4~                                           First model of bNAb sterile protection against CCR5-tropic AIDS virus                              Parren et al., [@B47]
                                                            Pre-challenge           b12                                                    25 mg/kg               RM                       IVa SHIV~SF162P3~                                           Fc receptor-dependent bNAb sterile protection                                                      Hessell et al., [@B20]
                                                            Pre-challenge           VRC01/PGT121                                           20--50/0.2--20 mg/kg   RM                       IR SHIV~AD8EO~/SHIV~DH12−V3AD8~                             bNAb sterile protection: serum titer \~1:100                                                       Shingai et al., [@B59]
                                                            Pre-challenge           PGT121                                                 2 mg/kg                RM                       IVa SHIV~SF162P3~                                           bNAb distal elimination of viral reservoir cells                                                   Liu et al., [@B34]
                                                            Pre-challenge           Weak NAb b6/ Non-NAb F240                              5 mg                   RM                       IVa SHIV~SF162P4~                                           No sterile protection by weak NAbs/non-NAbs                                                        Burton et al., [@B8]
                                                            Pre-challenge           Anti-HIV non-neut IgG from elite controllers           50 mg/kg               RM                       IR SHIV~SF162P3~                                            No sterile protection by non-NAbs despite high ADCC activity                                       Dugast et al., [@B12]
                                                            Days 1+4+7+10           VRC07−523+PGT121                                       10/40 mg/kg            Infant RM                Oral SHIV~SF162P3~                                          Elimination of viral reservoir establishment                                                       Hessell et al., [@B21]
  Adaptive immune-cell enhancement and improved prognosis   Pre-challenge           Polyclonal anti-SHIV neut IgG+b12                      200 mg/kg              Infant pigtail macaque   Oral SHIV~SF162P3~                                          Enhanced endogenous B-cell responses and delayed disease onset                                     Ng et al., [@B44]
                                                            Pre-challenge           Polyclonal anti-SHIV neut IgG+b12                      200 mg/kg              Infant RM                Oral SHIV~SF162P3~                                          Enhanced endogenous B-cell responses associated with lower set point viremia and longer survival   Jaworski et al., [@B27]
                                                            Days 1+14               Polyclonal anti-SIV neut IgG                           170 mg/kg              RM                       IV SIV~smE660~                                              Cases of sterile protection/viremia reduction, enhanced B-cell responses                           Haigwood et al., [@B18]
                                                            Day 7                   Polyclonal anti-SIV neut IgG                           300 mg                 RM                       IV SIV~mac239~                                              Augmented endogenous CTL-based elite control (-yr 2)                                               Iseda et al., [@B26]
                                                            Day 7                   Polyclonal anti-SIV non-neut IgG                       300 mg                 RM                       IV SIV~mac239~                                              No viremia reduction by non-NAbs despite ADCVI activity                                            Nakane et al., [@B42]
  Dose-dependent viremia reduction                          Days 16--22             3BC176+PG16+45−46^G54W^ +PGT128+10−1074                0.5 mg each            Humanized mice           IP HIV-1~YU2~                                               10--1000-fold decrease in viremia and delayed rebound                                              Klein et al., [@B29]
                                                            Week 12/157--163        3BNC117/10−1074                                        10 mg/kg               RM                       IR SHIV~AD8EO~                                              NAb dose-dependent viremia reduction                                                               Shingai et al., [@B60]
                                                            Month 9 (d0+7+222)      PGT121                                                 10 mg/kg               RM                       IR SHIV~SF162P3~                                            NAb dose-dependent viremia reduction/ chronic-phase T-cell functional recovery                     Barouch et al., [@B3]
                                                            Day 153/745             Polyclonal anti-SIV neut IgG                           170 mg/kg              RM rapid progressors     IV SIV~mac251~                                              Transient (\<24 h) viremia decrease                                                                Binley et al., [@B4]

*Slashes show differential regimens. Plus signs show combination of the regimens. Experiments using are shown in temporally descending order of (N)Ab infusion*.

*Neut, neutralizing; non-neut, non-neutralizing*.

*IVa, intravaginal; IR: intrarectal; IV, intravenous; IP: intraperitoneal challenge*.

Sterile protection and viremia suppression by passive NAbs {#s2}
==========================================================

The initial interest in the field of HIV antibodies was whether pre-challenge NAbs may actually provide sterile protection against the incoming virus. Early implications had been obtained in a report on SIV-challenged cynomolgus macaques (Putkonen et al., [@B51]), while viral quantitation (and thus evaluation of protectivity) was relatively suboptimal at that time. Later work demonstrated NAb sterile protection against CXCR4-tropic (X4-tropic) HIV in human lymphocyte-reconstituted immunodeficient mice (Gauduin et al., [@B14]) and X4-tropic SHIV (X4-SHIV) challenge in pigtail macaques (Shibata et al., [@B58]) and rhesus macaques (Mascola et al., [@B37], [@B38]; Baba et al., [@B1]). Further analysis on X4-SHIV models proposed theoretical requisite NAb titers (Nishimura et al., [@B46]) and also showed that the temporal window period permitting NAb-mediated sterile protection was very stringent (\<24 h) (Nishimura et al., [@B45]).

Next addressed was the fundamental question on how NAbs may protect against the more difficult-to-protect CCR5-tropic (R5-tropic) immunodeficiency viruses which propagate more dominantly *in vivo* in the acute phase as transmitted/founder strains (Keele et al., [@B28]). An early challenging work (Parren et al., [@B47]) showed that, as like against X4-SHIVs, bNAb b12 with sufficient titers can exert complete protection against R5-tropic SHIV (R5-SHIV) challenge (Table [1](#T1){ref-type="table"} and Figure [1B](#F1){ref-type="fig"}). This concept of R5-tropic virus sterile protection was further confirmed by several combinations of bNAbs and viral challenge routes (Veazey et al., [@B64]; Hessell et al., [@B23],[@B22], [@B24]). While it was first speculated that attainment of such sterile protection-conferring titers was rather difficult, recent studies have suggested that depending on the choice and potency of the passive bNAb, sterile protection may well be a feasible goal (Rudicell et al., [@B53]; Shingai et al., [@B59]). Another related new study has discovered that the biological half-life of the bNAbs determine the longevity of sterile protection against repeated SHIV challenges afforded by a single administration (Gautam et al., [@B15]). Based on the robust HIV/SIV-blocking efficacy *in vitro* as well as theoretically maximal "breadth," interest had also been taken in blocking the CD4 entry receptor itself by antibodies, while recently it was shown that straightforwardly blocking the viral Env by bNAbs was more effective (Pegu et al., [@B48]).

Alternatively, it was also found that polyclonal neutralizing IgG existing at viral challenge can confer slower disease onset as well as enhanced survival in orally R5-SHIV-infected newborn macaques, suggestive of a lasting protective effect by preexisting NAb titers (Ng et al., [@B44]; Jaworski et al., [@B27]).

Extended from these, recently it was found that even in established chronic-phase R5-SHIV infection (post-set point), potent anti-HIV bNAbs at high titers can also provide viremia suppression (Barouch et al., [@B3]; Shingai et al., [@B60]) (Table [1](#T1){ref-type="table"} and Figure [1C](#F1){ref-type="fig"}). In such models, plasma bNAb titers, viral suppression and rebound basically are linked in a pharmacological manner; i.e., decline in NAb titers results in viral escape and viremia recrudescence. Furthermore, a recent report of HIV viremia suppression in stably infected (\~20 days) humanized mice (Klein et al., [@B29]) (Table [1](#T1){ref-type="table"}) showed that, compared with bNAb monotherapy, tri-mix or penta-mix administration of bNAbs resulted in a much sharper decline in viremia as well as delay in viremia rebound; i.e., an increase in the number of simultaneous Env targeting resulted in additive and/or synergistic containment of viral replication. This result also provided a rationale of inducing and/or administering multiple epitope-specific (b) NAbs for maximal efficacy. Thus, pre-challenge NAb titers do provide sterile protection against AIDS virus challenge and viremia suppression can also be transiently attained by sufficient post-challenge NAb titers.

Innate immune-cell boosting by passive NAbs {#s3}
===========================================

How passive Ab administration may affect endogenous immune responses has been a long-standing important question. In the report on R5-SHIV sterile protection by b12 (Parren et al., [@B47]), the authors noted that NAbs, at sub-sterilizing titers, also derived cases of decreased viremia levels later on. Later, the group showed that the b12 sterile protection occurred *in vivo* in an Fc receptor- but not complement-dependent manner (Hessell et al., [@B20]), and associated with antibody-dependent cellular viral inhibition (ADCVI) (Forthal et al., [@B13]) activity *in vitro*. These innate (mainly natural killer) cell-dependent mechanisms were also explanatory of the above non-sterile protective effects. Another line of work showed engineered Fc receptor-binding properties of bNAb VRC01 being related with extended bioavailability, altered localization (antibody transcytosis) and improved protection against SHIV challenge (Ko et al., [@B30]). Recently, treatment-naïve HIV-infected patients manifested evidence for selective pressure by antibody-dependent cellular cytotoxicity (ADCC) even without exogenous Ab infusion (Chung et al., [@B11]), suggesting that augmenting this innate cell-dependent molecular/cellular axis may indeed be a promising strategy. Indeed, in HIV-1-infected humanized mice, enhanced binding against activating Fc receptors increased while its complete abrogation notably decreased bNAb-mediated viremia suppression (Bournazos et al., [@B7]), suggesting that innate cell modulation may also occur in established infection.

Adaptive immune-cell boosting by passive NAbs {#s4}
=============================================

Intimately linked with the above is how NAbs may influence adaptive cellular responses. In our SIV challenge-NAb passive immunization model, we found that early (day 7) passive polyclonal NAb infusion in SIV~mac239~-challenged rhesus macaques resulted in elevated myeloid DC-associated viral loads (Yamamoto et al., [@B67]), temporally followed by elevation of Gag-specific polyfunctional CD4^+^ T-cell responses and increased *in vitro* viral suppressive activity in CD8^+^ cells (Yamamoto et al., [@B68]) (Table [1](#T1){ref-type="table"} and Figure [1D](#F1){ref-type="fig"}). Extended from such findings, in this model we recently identified that these NAb-mediated CD8^+^ cells also acquired enhanced suppressive activity against a panel of immunodominant CTL escape mutants, providing stringent T cell-based SIV control for up to 2 years without accumulation of viral CTL escape mutations (Iseda et al., [@B26]). This poses a possibility that the total virus-specific CTL population in NAb-infused animals became resistant against arousal of SIVs with CTL escape mutations *in vivo*, contributing to the prevention of CTL escape mutation accumulation. This early CTL "functional broadening" in NAb-infused macaques also may be related with the identified direct DC-mediated CTL cross-priming activity of the infused NAbs, suggestive of Ab/APC-dependent epitope spreading. Upon attainment of this stable SIV control, the originally immunodominant epitope-specific CTLs became preserved (presumably due to early CTL broadening) and showed stimuli-specific metabolic quiescence, as defined by enrichment of a phosphorylated AMP kinase-low CTL subpopulation which is indicative of exhaustion-free T-cell qualitative preservation (Blagih et al., [@B5]). Thus, NAb-boosted T cell-based primary SIV control also secondarily results in functional preservation of the most potent CTLs, which in turn may have further stabilized the viral control.

The above results collectively well explained SIV control in the animals, i.e., by passive NAb-mediated improved acute-phase CD4^+^/CD8^+^ T-cell priming. Alternatively, in another two-dose (days 1 plus 14) polyclonal NAb infusion model, cases of sterile protection and set-point viremia reduction were obtained in SIV~smE660~-challenged macaques, and this associated with enhanced endogenous *de novo* NAb responses (Haigwood et al., [@B19], [@B18]). These similar phenotypes triggering different endogenous immune effector responses may stem from the different properties of the challenge virus strain (i.e., SIV~mac239~ is highly NAb-resistant and induces NAb responses only rarely and in the chronic phase). Importantly, this pattern of synergism between endogenous adaptive immune cells and early short-term NAb administration has also become well-conceptualized in murine retrovirus-infected mice (Gros et al., [@B17]; Michaud et al., [@B40]; Nasser et al., [@B43]), further emphasizing the importance of actively modifying T-cell and/or B-cell responses through coexisting NAbs.

In the aforementioned chronic-phase SHIV viremia suppression study (Barouch et al., [@B3]), bNAb infusion in macaques similarly provided an increase in CTL viral suppressive activity. Given that virus-specific CTLs show considerable functional exhaustion due to antigen load in chronic infection (Streeck et al., [@B61]), this post-NAb infusion increase in viral suppression may reflect a functional recovery, and hence may also involve viremia decrease itself in the recovery process.

Another well-designed AIDS model utilizes infant macaques to evaluate the direct impact of NAbs on impeding pathogenic progression with a clear-cut disease phenotype. Here, pre-challenge polyclonal and monoclonal NAbs conferred enhanced endogenous B-cell responses against oral R5-SHIV challenge and protection against disease onset (Ng et al., [@B44]; Jaworski et al., [@B27]). This may be a consequence of CD4^+^ T-cell protection, or due to some pattern of indirect B-cell modulation, such as NAb-mediated Env antigenic modulation (Schoofs et al., [@B57]). Conversely, late-phase polyclonal NAb infusion in immunocompromised SIV-infected rapid progressors showed no protective effect (Binley et al., [@B4]), suggesting the importance of intact endogenous immunity for NAb-mediated viral suppression. Taken together, results collectively show that NAbs provide a wide spectrum of protective mechanisms *in vivo*, particularly those involving Fc receptors (Lambour et al., [@B32]), against AIDS virus replication.

Comparison between passive NAbs and drug therapy {#s5}
================================================

How passive NAbs, which indeed are soluble effectors, may be pharmacologically compared for its impact with (combined) antiretroviral therapy \[(c)ART\] is another important point. One work on the effect of acute-phase ART on SIV-infected rhesus macaques (Kubo et al., [@B31]) showed that initiation of ART as early as day 2 (and up to day 28) still does not eliminate *in vivo* virus, as demonstrated by rapid rebound of viremia. Another further systematic analysis on temporal establishment of *in vivo* viral reservoir seeding showed that past day 3 post-SIV challenge, the time until initiation of cART is proportionate to the speed of viremia rebound after therapy cessation (Whitney et al., [@B65]) (Figure [1E](#F1){ref-type="fig"}). This implicates that the acknowledged notion of "hit early and hard" for drug therapy (Ho, [@B25]) also partially applies to the superacute phase, while attainment of complete viral eradication by ART is still an independent and extremely high final hurdle. This potentially may require host dispositions different from ones associated with elite HIV control such as possession of protective major histocompatibility complex class I (MHC-I) alleles, as implicated in the VISCONTI study in which early cART-treated patients with no viral rebound did not possess them (Sáez-Cirión et al., [@B54]).

In stark contrast, a recent important report showed that superacute-phase (days 1--10) administration of bNAbs (Hessell et al., [@B21]) results in an elimination in virus-detectable tissue compartments throughout the body for 6 months. Another cutting-edge report (Liu et al., [@B34]) tracked previously underscored post-infection viral replication *in situ* deriving transcriptomic signatures of antiviral gene up-regulation in infected foci (Barouch et al., [@B2]), and its abortion by *in vivo* titers of bNAb PGT121 at viral challenge. These two essentially may highlight a common notion of literally purging the eclipse phase of initial viral infection/dissemination by NAbs. It remains to be clarified whether the slightly earlier moment of NAb infusion derives the protection not obtained by early cART, or if other effector functions of NAbs unavailable by drugs mediate the protective effect. Our model of an acute-phase single NAb infusion resulting in sustained SIV control (Iseda et al., [@B26]) is most suggestive for the latter. Implications are also provided by a report showing that a combined bNAb single shot at day 10 post-SHIV infection derives protective effects substituting and comparable to that of a daily ART regimen for the next 11 days (Bolton et al., [@B6]). Taken together, NAbs do appear to exert protective effects unavailable by antiretroviral therapy.

Requisite of neutralizing activity in passive antibody-based viral prevention and control {#s6}
=========================================================================================

Whether direct virus-neutralizing activity is required for antibody-mediated AIDS virus control is critical. A very important report showed that for attaining stringent sterile protection against R5-SHIV challenge, neutralizing activity is indispensable (Burton et al., [@B8]). This notion was confirmed by another group, which showed that regardless of possessing potent Fc effector functions \[ADCC and antibody-dependent cellular phagocytosis (ADCP) (Pelegrin et al., [@B49])\], antibody sterile protection was not obtained by pre-infection non-NAbs (Dugast et al., [@B12]) (Table [1](#T1){ref-type="table"}). Similarly, in acute-phase infection, polyclonal non-NAb infusion at day 7 achieved no SIV viremia control in our model (Nakane et al., [@B42]). We very recently compared viral suppressive activity in our aforementioned polyclonal NAb- and non-NAb-infused rhesus macaques, and found that CD8^+^-cell viral suppressive activity is selectively enhanced in NAb-infused but not in non-NAb-infused animals (Yamamoto et al., [@B66]). This means that in addition to the availability of direct virus neutralization, such property of antiviral antibodies may also directly affect modulation patterns of cellular immune responses and further impact disease prognosis.

Passive NAb immunotherapy in HIV-infected humans {#s7}
================================================

Based on recent characterization of various bNAbs, their application as immunotherapeutic agents has started to extensively proceed in human trials. Preceding this current trend, insights had been obtained by one early clinical trial (Trkola et al., [@B63]), which showed that earlier administration of bNAbs against HIV-infected humans resulted in more delayed viremia rebound in several patients. In addition to considerations on such endogenous baseline status of the patients to be treated, another current interest is how the previously monitored association of virological control and (b) NAb pharmacological properties can be extrapolated from mice and non-human primates to humans.

In one representative study, single administration of a well-characterized potent CD4 binding site-specific bNAb VRC01 to HIV-infected patients was reported to exert 1.1--1.8 log10 reduction in viremia (Lynch et al., [@B35]). This single injection also derived emergence of VRC01-resistant strains, suggesting the necessity of either modifying or combining the NAbs to be infused.

Administration of another extremely potent CD4 binding site-specific bNAb 3BNC117, at a modest dose (30 mg/kg), also resulted in significant 0.8--2.5 log10 reduction in viremia (Caskey et al., [@B10]). 3BNC117 administration in HIV-infected humans also resulted in suppression of viral rebound during cART interruption (Scheid et al., [@B55]), highlighting the feasibility of and strong selective pressure exerted by this bNAb infusion. Furthermore, 3BNC117 administration in HIV-infected viremic individuals resulted in altered endogenous B-cell responses, as analyzed by changes in viral Env and B-cell receptor phylogenetic polymorphisms (Schoofs et al., [@B57]).

In another cohort, administration of an Env variable region 3 (V3)-specific bNAb KD-247 resulted in decreased viremia in HIV-infected patients, as well as an obtained case of ongoing viremia control after NAb decline (Matsushita et al., [@B39]), showing that a V3-specific bNAb can also mediate viral suppression. This bNAb further holds promise for host protection in that it may give synergistic protective effects with CD4-mimetic chemical compounds (Yoshimura et al., [@B70]). This and other types of NAb/chemical compound synergisms (Yoshimura et al., [@B69]; Madani et al., [@B36]) may become important strategies, particularly in NAb-based immunotherapies.

Collectively, these reports are now starting to provide a proof-of-concept for the notions initially obtained in animal AIDS models of NAb passive immunization.

Concluding remarks {#s8}
==================

NAbs, when present by passive immunization, are being recognized as capable of playing a central role in sterile protection against and post-infection control of SIV and SHIV infection. Future studies aiming for NAb immunotherapy-based HIV clinical control shall proceed with a pharmacological perspective on the *in vivo* spectrum/dosage as well as Fc-mediated effector functions of the (b) NAbs to be infused. For prophylactic vaccine induction of HIV-specific NAbs, in addition to the rational design of vaccine Env antigen, designing attainment of synergism with concomitantly induced T-cell responses may delineate protective responses much more potent than what is currently expected.
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